Orflo Raises $3.0 Million Of Growth Capital To Support Continued Expansion
4/17/2014 10:19:22 AM
April 17, 2014 -- Innovator in cell & protein analysis increases support of Moxi Flow launch Hailey, Idaho – Orflo Technologies, an innovator of cell analysis and flow cytometry solutions in life science research and applied markets, today announced it has completed its financing of $3.0 million of growth capital. The round was led by BroadOak Capital Partners and included participation from Research Corporation Technologies, Inc. The proceeds will be used to support the company’s recent launch of its Moxi Flow cassette-based Smart Flow Cytometer™. In addition, it will enable expanding applications and improvements to the platform; including multiplex capabilities.
"Orflo’s commitment to simplifying cell analysis with highly functional, easy-to-use, tools is impressive. Their products represent a new approach to using proven technologies.” said Bill Snider, Managing Partner, BroadOak Capital Partners.
“We are glad to support Orflo’s efforts to develop and launch innovative solutions for cell and protein analysis.”
Ted Ayliffe, PhD, Orflo CEO, said “This recent financing allows us to further our mission of delivering cost-effective solutions that accelerate scientific discovery by simplifying the tools researchers use most often. We will continue to create enabling technologies that empower every lab to perform relatively complex experiments with paradigm shifting plug-and-play simplicity.”
Orflo Technologies is a life sciences company developing and marketing revolutionary instrumentation for the cell analysis industry. Since our first invention of the pipette-based cell counter, the core of Orflo’s instrumentation has been a patent protected disposable, micro-fluidic, electro-optic flow cell. Through the unique combination of electric impedance (Coulter Principle) and fluorescence based flow Cytometry detection modes, Orflo’s instruments provide a powerful, unique window to cell analysis by directly measuring fluorescence and cell volume simultaneously. This capability, coupled with the simplicity, affordability, and elimination of all fluidics and maintenance, will enable a significant increase in the pace of experimentation, testing and ultimately discovery.
For more information, please visit www.orflo.com Contacts Orflo Technologies Investors and Media Don O’Neil (760) 908-8369, email@example.com
Help employers find you! Check out all the jobs and post your resume.
comments powered by